Amgen Reply Brief Addresses Mischaracterizations by Sanofi, U.S. Government on Proper Enablement Inquiry for Genus Claims
Copyright Claims Board Finds for Photographer on Infringement But Curbs Damages in First Final Decision
Vidal Vacates PTAB Denial of IPR Institution in Second Decision this Week on Compelling Merits Analysis